Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP) 1 . FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genomewide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 × 10 -11 ; odds ratio, minor allele (C) 0.61, 95% CI 0.53-0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 × 10 -4 ). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.
l e t t e r s
Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP) 1 . FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genomewide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 × 10 -11 ; odds ratio, minor allele (C) 0.61, 95% CI 0.53-0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 × 10 -4 ). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.
FTLD manifests clinically with progressive behavioral and/or language problems with a prevalence of 3.5-15 per 100,000 in people 45-64 years of age [2] [3] [4] [5] . The clinical presentation of individuals with FTLD patho logy varies depending on the referral base 6 , and among these indi viduals, ~50% are diagnosed as having FTLDTDP 1 . A family history of a similar neurodegenerative disease may be present in up to 50% of individuals with FTLD, supporting the existence of a genetic pre disposition to the disease 7 . Autosomal dominant GRN mutations occur in ~20% of individuals with FTLDTDP [8] [9] [10] [11] . GRN mutations are lossoffunction mutations, with most causing nonsensemediated RNA decay as a result of premature termination of the mutant tran script, and with the ensuing haploinsufficiency causing disease 11, 12 . However, a substantial number of cases of familial FTLDTDP are Common variants at 7p21 are associated with fronto temporal lobar degeneration with TDP43 inclusions l e t t e r s not explained by GRN mutations. Further, individuals with the same GRN mutation show varying clinical phenotypes and ages of disease onset, a pattern that is likely to reflect the presence additional genetic and environmental factors 13 .
The genomewide association (GWA) phase of the study included 515 individuals with FTLDTDP (cases) and 2,509 population con trols without FTLDTDP genotyped on Illumina HH550 or 610Quad BeadChips as described 14 (Table 1) . A large population control cohort was acceptable for use in this study because the generalpopulation incidence of FTLD is low 4, 5, 15 . Cases were obtained under institu tional review board approval by members of the International FTLD Collaboration consisting of investigators from 45 clinical centers and brain banks representing 11 countries (United States, Canada, United Kingdom, The Netherlands, Belgium, Spain, Germany, Australia, Finland, France and Sweden). All cases met either pathological (n = 499) or genetic (n = 16) criteria for FTLDTDP, which was confirmed by detecting TDP43 inclusions using immunohistochemistry 1, 16 . A genetic criterion for inclusion (the presence of a known pathogenic GRN mutation) was used because individuals with FTLD who have GRN mutations are always diagnosed as having FTLDTDP 8, 9, 17, 18 . All cases were checked for relatedness using identity by state (IBS). The results confirmed that, although some GRNassociated FTLDTDP cases share the same mutation on chromosome 17 with similarity in the immediate vicinity of GRN, they are no more related in the remainder of the genome than individuals without GRN mutations. Detailed inclusion criteria are provided in the Online Methods; cohort features are described in Supplementary Table 1 .
CochranArmitage trend test statistics were calculated at all mark ers after qualitycontrol filtering. In addition to selfreported ancestry, all cases and controls were initially screened at ancestryinformative markers using the STRUCTURE software package 19 to reduce the risk of population stratification from selfreported ancestry alone. Each case was subsequently matched to four controls by 'genetic match ing' by smartPCA 20 as previously described 21 . The genomic infla tion factor () for this study was 1.05, indicating that background stratification was minimal, as demonstrated in quantilequantile plots (Supplementary Fig. 1 ).
Three SNPs reached genomewide significance after Bonferroni correction (Fig. 1a,b) . All three SNPs (rs6966915, rs1020004 and rs1990622) mapped to a 68kb interval (Supplementary Fig. 2 ) on 7p21.3 (top marker, rs1990622, minor allele frequency (MAF) 32.1% in cases and 43.6% in controls, odds ratio (OR) = 0.61, 95% CI 0.53-0.71, P = 1.08 × 10 -11 ). For rs1990622, the more common (T) allele confers risk with an OR of 1.64 (95% CI 1.34-2.00). The interval contained nine additional markers in strong linkage disequilibrium (LD) (r 2 > 0.45) that were also associated with FTLDTDP (P value range, 8.9 × 10 -3 -7.5 × 10 -7 ; OR range 0.63-0.77) ( Table 2 ). All 12 associated SNPs mapped to a single LD block spanning TMEM106B, which encodes an uncharacterized transmembrane protein of 274 amino acids (Fig. 1b,c) . rs1020004 and rs6966915 lie within introns 3 and 5, respectively, of TMEM106B, whereas rs1990622 is 6.9 kb downstream of the gene.
The association of the 7p21 locus with FTLDTDP was replicated by TaqMan SNP genotyping in 89 independent cases with FTLDTDP and 553 selfidentified Europeandescended controls at two of the l e t t e r s genomewide-significant SNPs (rs1020004 and rs1990622) ( Table 1 and Supplementary Table 2) . A polymorphic variant adjacent to rs6966915 interfered with our interpretation of the TaqMan geno typing, precluding its use in the replication. The replication set was selected based on the same pathological criteria and had simi lar characteristics as the GWA cohort (Supplementary Table 1 ).
In this replication cohort, the top SNPs again showed significant association (P = 0.004 for rs1020004 and P = 0.0002 for rs1990622) with the same directions of association as those found in the GWA phase (Supplementary Table 1 ). These results suggest that the 7p21 locus, encompassing TMEM106B, represents a common genetic susceptibility locus for FTLDTDP. Notably, this association was not confirmed in a cohort of 192 living cases with unselected FTLD (Supplementary Table 2 ). This likely reflects heterogeneity in neuropathological substrates underlying FTLD because only ~50% of unselected clinical cases with FTLD are expected to have FTLD TDP. Assuming that TMEM106B genetic variants confer specific risk of FTLDTDP, the power to detect this association in 192 clini cal FTLD cases and 553 controls is ~30% for an  of 0.05. To have >90% power to detect this association, a clinical FTLD cohort would require more than 1,400 clinical cases with FTLD and an equal number of controls.
We next evaluated TMEM106B gene expression in different human tissues to iden tify possible phenotypeassociated differential expression and potential genetic regulators of expression. We queried the mRNAbySNP browser (see URLs; last accessed 6 June 2009), for genetic regulators of TMEM106B expres sion (eSNPs) in lymphoblastoid cell lines 22 . The top SNP, rs1990622, was significantly cor related with TMEM106B average expression levels (log 10 odds (LOD) 6.32; P = 6.9 × 10 -8 ), as was rs1020004 (LOD 5.16, P = 1.1 × 10 -6 ). The risk allele (T) of rs1990622 was associ ated with a higher level of mRNA expression, indicating that TMEM106B may be under cis regulation either by the FTLDTDPassociated SNPs or by one or more SNPs in LD with the associated variants. As the expression data in the publicly available database is derived from lymphoblastoid cell lines from individuals without FTLD TDP 22 , and the diseased organ in FTLDTDP is the brain, we won dered whether a similar correlation between genotype and expression phenotype for TMEM106B is also present in tissue types affected by disease, as well as in diseased individuals themselves. Accordingly, we used total RNA isolated from postmortem brains of individu als with FTLDTDP (n = 18) and neurologically unaffected control individuals (n = 7) to evaluate TMEM106B expression in the frontal cortex, which is severely affected in FTLDTDP, by quantitative RTPCR (QRTPCR). All RNA samples used were confirmed to be of equivalently high quality as described 23 (Supplementary Table 3) . For the same individuals for whom we obtained expression data, we genotyped rs1020004 and rs1990622 using allelic discrimina tion assays. Corroborating our results from the cell lines, expres sion of TMEM106B was significantly correlated with TMEM106B genotype, with riskallele carriers showing higher gene expression (for rs1990622, overall P = 0.027; TT compared to TC, P = 0.017; TT compared to CC, P = 0.03; Fig. 2a and Supplementary Fig. 3a) . Notably, however, expression of TMEM106B was >2.5 times higher in cases with FTLDTDP as compared to unaffected controls (P = 0.045; Fig. 2b ). In addition, the effects of an individual's genotype . Carriers of the GRN mutation had significantly higher levels of TMEM106B expression (overall P = 0.0009; cases with GRN mutations versus controls, P = 0.0005; cases with GRN mutations verses those without, P = 0.002). (d) When only cases heterozygous at rs1990622 (n = 14) were evaluated, GRN mutations remained significantly associated with a higher level of TMEM106B expression (P = 0.039) in the frontal cortex. QRT-PCR was performed in triplicate for all expression studies. Expression values were normalized to the geometric mean of two housekeeping genes and are shown here relative to a single reference control sample 23 . Error bars, s.e.m. Normalized gene expression data and sample genotype and gender data used for these analyses are provided in supplementary Data 1 and 2. 
e t t e r s
and TMEM106B expression levels on risk of developing disease are at least partly independent, as are the effects of genotype and disease status on TMEM106B expression (Supplementary Table 4) . Thus, these data suggest that increased TMEM106B expression in the brain might be linked to mechanisms of disease in FTLDTDP and that risk alleles at TMEM106B confer genetic susceptibility by increasing gene expression.
The primary criterion for inclusion in the GWA study (GWAS) was a neuropathological diagnosis of FTLDTDP; therefore, we studied all cases together regardless of GRN mutation status. Nevertheless, it was difficult a priori to predict whether additional genetic susceptibility loci would be identified in a group with Mendelian inheritance of highly penetrant mutations, such as mutations in GRN. We therefore separately evaluated FTLDTDP cases with (n = 89) and without (n = 426) GRN mutations. Asso ciation to the 7p21 locus persisted in both the GRN mutationnegative and -positive groups, and there was no significant hetero geneity in the ORs for the diseaseSNP association between the groups (Fig. 3 and Supplementary Tables 2 and 5) . Using family history status as a covariate in a logistic regression analysis showed that the 7p21 association is independent of family history (Supplementary Table 6 ). Thus, TMEM106B variants may act as modifiers in the presence of GRN mutations, just as the APOE locus has been shown to modify the age of onset of Alzheimer's disease in individuals with PSEN1 or PSEN2 mutations 24, 25 .
Additionally, in the entire GWA cohort, we observed a correla tion between rs1020004 genotype and disease duration (P = 0.03), with homozygotes for the risk allele (AA, wildtype) having a shorter duration of disease (that is, more severe disease) than individuals homozygous for the minor allele (GG; Supplementary Fig. 4) . These results provide strong confirmatory evidence for association of the 7p21 locus with increased risk for FTLDTDP in both individuals with and those without GRN mutations.
In addition to the 7p21 locus, analysis of the cases with GRN muta tions alone showed highly significant association with SNPs near the GRN locus on 17q21 (Fig. 3 and Supplementary Table 7) . As expected, haplotype analysis of these cases indicated that the chromo some 17 association was driven by a shared haplotype among the Arg493Stop (1477C>T) mutation carriers, which represented 20.2% (18 out of 89) of the cases with the GRN mutation. To determine if the observed association at the GRN locus was dependent on the asso ciation at the TMEM106B locus, we carried out a logistic regression analysis conditioning on the most significantly associated SNP at the 7p21 locus, rs1990622, in the cases with GRN mutations. The con ditional analysis had no effect on the association at the GRN locus, suggesting that the associations with 17q21 and 7p21 are independent. IBS analysis confirmed that these individuals are unrelated; therefore, the identified association on chromosome 7 cannot be discounted in carriers of the GRN mutation. Indeed, conditioning on the top SNP at the GRN locus, rs8079488, also had no effect on the TMEM106B association (data not shown). The GWAS of cases without the GRN mutation showed a trend for association at five other loci besides 7p21 (Supplementary Table 8) , including a locus on chromosome 9p21.2 that falls within a 7.7Mb interval critical for risk of a form of FTLD with MND defined from five previous linkage studies, representing a potential refinement of that region 26 . We observed no association at the GRN locus in the cases without GRN mutations.
We then evaluated mRNA expression of TMEM106B in FTLDTDP cases with and without GRN mutations separately, and the cases with GRN mutations showed increased expression (overall P = 0.0009) compared to both controls (P = 0.0005) and FTLDTDP cases without GRN mutations (P = 0.002) (Fig. 2c) . Further, after we controlled for rs1990622 genotype and focused on heterozygotes (n = 14), the presence of a GRN mutation remained significantly associated with increased TMEM106B expression (P = 0.039; Fig. 2d ) as compared to normal controls. These results are compatible with a model in which mutations in GRN are upstream of increased TMEM106B expression in increasing the risk for FTLDTDP.
A mechanistic understanding of the pathogenesis of FTLD has been hampered by the heterogeneity in clinical and pathological features. With the discovery of TDP43 as a major FTLD disease protein, the pathologically defined entity of FTLDTDP emerged 16 . Identification of GRN mutations as a major genetic cause of FTLDTDP led to the definition of a genetic subgroup of FTLDTDP. This study identifies TMEM106B as a genetic risk factor for FTLDTDP. We speculate that the homogeneous, pathologically defined study population used here enabled us to detect a robust signal with a relatively small number of cases. and 17. The chromosome 17 association was confirmed to be driven by a shared haplotype in carriers of the C1477T (R493X) mutation in GRN, representing ~20% of mutationpositive cases; however, the chromosome 7 association is not related to any single GRN mutation and remains when the cases with the C1477T mutation are removed from the analysis (P = 1.4 × 10 -10 ). The same locus on chromosome 7 identified in the cases with the GRN mutation is also the strongest signal in the cases without the GRN mutation, although it does not reach genome-wide significance.
A list of the SNPs with the highest signals in b is given in supplementary table 8.
l e t t e r s
Our data suggest a potential disease mechanism in which risk associated polymorphisms at 7p21 increase TMEM106B expression and elevated TMEM106B expression increases risk for FTLDTDP. Additionally, we show that TMEM106B genotypes are an important risk factor for FTLDTDP even in GRN mutation carriers, implying that GRN mutations may act upstream of TMEM106B in a patho genic cascade. Future directions of research on this newly discovered genetic risk factor will include a detailed evaluation of the TMEM106B locus by sequencing, collection of more cases with pathologically defined FTLDTDP for a genomewide replication, and studies of expression profiles in additional tissues and brain regions. A better understanding of this gene may in turn provide an opportunity for clinical intervention in an otherwise fatal and devastating neuro degenerative disease. l e t t e r s using the ∆∆C T method 29 , and the geometric mean of two housekeeping genes (encoding βactin and cyclophilin A) were shown to have stable expression in frontal cortex samples from FTLDTDP and normal individuals 23 . 
